# US 10,246,514 B2 · Single domain antibodies that bind to human CD20

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,246,514 B2
- Document ID: US10246514B2
- Status: Granted
- Kind: B2
- Application number: 15/701,530
- Filed: 2017-09-12
- Published: 2018-03-22
- Granted: 2019-04-02
- Earliest claimed: 2016-09-12
- Assignees: The United States of America as represented by the Secretary of the Navy
- Applicants: The United States of America, as represented by the Secretary of the Navy
- Inventors: Jinny Lin Liu; Daniel Zabetakis; Ellen R. Goldman; George P. Anderson
- Web page: https://patentgrep.com/patent/US10246514B2

## CPC

- C07K 16/2887: {against CD20}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 39/39533: {against materials from animals}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein is the development of recombinant single domain antibodies, also known as nanobodies, that may provide better therapeutic results or be useful for diagnostic applications of B-cell lymphomas, or in other applications where an antibody to CD20 may be useful.

## Claims

### Claim 1

An isolated anti-CD20 single domain antibody comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 5, or SEQ ID NO: 6.

### Claim 2 (depends on 1)

The isolated anti-CD20 single domain antibody of claim 1, wherein the amino acid sequence is that of SEQ ID NO: 2 or SEQ ID NO: 6.

### Claim 3

An isolated anti-CD20 single domain antibody comprising the amino acid sequence of SEQ ID NO: 16.

### Claim 4

A pharmaceutical composition comprising:
an isolated anti-CD20 single domain antibody comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 5, or SEQ ID NO: 6;
and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the amino acid sequence is that of SEQ ID NO: 2 or SEQ ID NO: 6.

### Claim 6

A pharmaceutical composition comprising:
an isolated anti-CD20 single domain antibody comprising the amino acid sequence of SEQ ID NO: 16;
and a pharmaceutically acceptable carrier.